Sobi's Q2 2025 Financial Report: A Strong Performance
Swedish Orphan Biovitrum AB, commonly known as Sobi®, has recently released its report for the second quarter of 2025, showcasing impressive financial growth and maintaining momentum in its portfolio and development pipeline. According to the reported figures, Sobi's total revenue soared by 13%, marking a considerable increase to SEK 6,175 million compared to SEK 5,442 million in the same period last year. Notably, this growth was propelled by a 22% increase when factoring in constant exchange rates.
Haematology Business Thrives
Sobi's haematology segment played a pivotal role in this success, with revenues jumping by 27% at constant exchange rates, totaling SEK 4,570 million, up from SEK 3,866 million. This surge was primarily driven by the successful launch of
Altuvoct, which contributed SEK 627 million. Other key products, such as
Doptelet, with sales reaching SEK 1,220 million, and
Aspaveli/Empaveli at SEK 304 million, also bolstered the company's performance, despite a slight decline in
Vonjo sales which recorded SEK 302 million, down from SEK 347 million.
Immunology Segment Shows Resilience
In addition to haematology, Sobi's immunology revenue grew by 11% at constant exchange rates, amounting to SEK 1,288 million, slightly up from SEK 1,277 million. The segment saw strong performances from
Gamifant and
Kineret, generating sales of SEK 632 million and SEK 749 million respectively. This consistent growth reflects Sobi's robust position in the rare disease market, thanks to its strategic focus on targeted innovations.
Strategic Portfolio Success
The strategic portfolio, which includes key treatments such as Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo, and Zynlonta, reported a remarkable 65% increase in revenue at constant exchange rates, totaling SEK 3,384 million compared to SEK 2,224 million a year earlier. This significant earnings boost underscores Sobi's commitment to advancing healthcare solutions for patients with rare diseases.
Earnings and Future Outlook
Adjusted earnings before interest, taxes, depreciation, and amortization (EBITA) margin improved to 34% from 28%, resulting in EBITA of SEK 1,863 million — representing a margin of 30%, up from 27%. The company noted an increase in earnings per share (EPS) before dilution to SEK 1.85 from 0.66, with diluted EPS at SEK 1.83 compared to 0.65 previously. Even after adjustments for comparability, the EPS stood at SEK 2.38 before dilution.
Looking ahead, Sobi maintains its revenue growth guidance for 2025, projecting a high single-digit percentage increase at constant exchange rates, with expectations of adjusted EBITA margins remaining in the mid-30s.
Investor Engagement
In light of these results, Sobi invites investors, analysts, and the media to participate in a conference call scheduled for the same day at 14:00 CEST (1300 GMT / 0800 EST). The conference will provide a detailed presentation of the results, followed by a Q&A session. Interested parties can access the presentation live on the Sobi website, with accompanying slides made available prior to the call.
About Sobi
Sobi is a biopharmaceutical company dedicated to unlocking breakthrough innovations to transform the lives of people with rare diseases. With around 1,900 employees globally and a revenue of SEK 26 billion in 2024, Sobi continues to expand its footprint in the biopharma industry. Its shares are listed on Nasdaq Stockholm under the ticker symbol (STO SOBI).
For further information about Sobi, visit
sobi.com.